HYDROmorphone HCl 6 mg/30 mL in 0.9% Sodium Chloride Injection, (Concentration = 0.2 mg/ml) 30 mL...

FDA Drug Recall #D-0405-2024 — Class II — November 9, 2023

Recall Summary

Recall Number D-0405-2024
Classification Class II — Moderate risk
Date Initiated November 9, 2023
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm SCA Pharmaceuticals, LLC
Location Windsor, CT
Product Type Drugs
Quantity 5,734 syringes

Product Description

HYDROmorphone HCl 6 mg/30 mL in 0.9% Sodium Chloride Injection, (Concentration = 0.2 mg/ml) 30 mL fill 35 mL Plungerless Syringe, Rx only, SCA Pharmaceuticals, 755 Rainbow Rd., Windsor, CT 06095, NDC 70004-0300-16, Bar Code 70004030016

Reason for Recall

Lack of Assurance of Sterility

Distribution Pattern

Nationwide in the USA

Lot / Code Information

Lot #: 1223048530, Exp 11/22/23; 1223048692 Exp 11/29/23; 1223048739 EXP 11/30/23; 1223048826 Exp 12/05/23; 1223048963 Exp 12/08/23; 1223048964 EXP 12/11/23; 1223049111 Exp 12/15/23; 1223049128 Exp12/19/23; 1223049210 EXP 12/21/23; 1223049234 Exp 12/22/23; 1223049257 Exp 12/22/23; 1223049322 Exp 12/27/23; 1223049416 Exp 12/28/23; 1223049528 Exp 01/03/24; 1223049559 Exp 01/04/24; 1223049614 Exp 01/05/24; 1223049632 Exp 01/08/24; 1223049725 Exp 01/11/24; 1223049792 Exp 01/15/24; 1223049793 Exp 01/15/24; 1223049905 Exp 01/19/24; 1223050029 Exp 1/24/24; 1223050061 Exp 01/25/24; 1223050179 Exp 01/29/24

Other Recalls from SCA Pharmaceuticals, LLC

Recall # Classification Product Date
D-0417-2024 Class II PHENYLephrine HCl 5000 mcg/50 mL in 0.9% Sodium... Nov 9, 2023
D-0399-2024 Class II fentaNYL 100 mcg/50 mL, Bupivacaine HCl 0.125% ... Nov 9, 2023
D-0411-2024 Class II labetalol HCl 20 mg/4mL Injection, (Concentrati... Nov 9, 2023
D-0410-2024 Class II HYDROmorphone HCl 30 mg/30 mL in 0.9% Sodium Ch... Nov 9, 2023
D-0419-2024 Class II PHENYLephrine HCl 40 mg in 0.9% Sodium Chloride... Nov 9, 2023

Frequently Asked Questions

Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.